Ed Kim, Senior Vice President and Physician-in-Chief at City of Hope Orange, shared a post on LinkedIn:
“One of the most rewarding parts of oncology research is seeing an idea move from the laboratory to a clinical trial and ultimately to patients.
Today’s FDA approval of daraxonrasib is a powerful example of that journey.
City of Hope participated in the pivotal clinical trial that vaulted this targeted therapy forward. Our national clinical trials network accelerated access to this therapy for our patients across the country through the FDA-authorized Expanded Access Program.
Each new treatment option matters. It reflects years of scientific discovery, rigorous clinical evaluation and the willingness of patients to participate in research that may help both them and future generations.
Thank you to Pashtoon Kasi, Vincent Chung, and physicians, researchers and teams across the country for always putting the needs of our patients first.
Moments this reinforce why we continue to invest in research and clinical trials at City of Hope – today, tomorrow and beyond.”
You can also read: FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
